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Summary
Background Artemisinins, the most eﬀ ective antimalarials available, are not recommended for falciparum malaria 
during the ﬁ rst trimester of pregnancy because of safety concerns. Therefore, quinine is used despite its poor 
eﬀ ectiveness. Assessing artemisinin safety requires weighing the risks of malaria and its treatment. We aimed to 
assess the eﬀ ect of ﬁ rst-trimester malaria and artemisinin treatment on miscarriage and major congenital 
malformations.
Methods In this observational study, we assessed data from antenatal clinics on the Thai–Myanmar border between 
Jan 1, 1994, and Dec 31, 2013. We included women who presented to antenatal clinics during their ﬁ rst trimester with 
a viable fetus. Women were screened for malaria, and data on malaria, antimalarial treatment, and birth outcomes 
were collected. The relationship between artemisinin treatments (artesunate, dihydroartemisinin, or artemether) and 
miscarriage or malformation was assessed using Cox regression with left-truncation and time-varying exposures.
Findings Of 55 636 pregnancies registered between 1994 and 2013, 25 485 pregnancies were analysed for ﬁ rst-trimester 
malaria and miscarriage, in which 2558 (10%) had ﬁ rst-trimester malaria. The hazard of miscarriage increased 
1·61-fold after an initial ﬁ rst-trimester falciparum episode (95% CI 1·32–1·97; p<0·0001), 3·24-fold following 
falciparum recurrence (2·24–4·68; p<0·0001), and 2·44-fold (1·01–5·88; p=0·0473) following recurrent symptomatic 
vivax malaria. No diﬀ erence was noted in miscarriage in ﬁ rst-line falciparum treatments with artemisinin (n=183) 
versus quinine (n=842; HR 0·78 [95% CI 0·45–1·34]; p=0·3645) or in risk of major congenital malformations 
(two [2%] of 109 [95% CI 0·22–6·47] versus eight (1%) of 641 [0·54–2·44], respectively).
Interpretation First-trimester falciparum and vivax malaria both increase the risk of miscarriage. We noted no evidence of 
an increased risk of miscarriage or of major congenital malformations associated with ﬁ rst-line treatment with an 
artemisinin derivative compared with quinine. In view of the low eﬃ  cacy of quinine and wide availability of highly eﬀ ective 
artemisinin-based combination therapies, it is time to reconsider ﬁ rst-trimester antimalarial treatment recommendations.
Funding The Wellcome Trust and The Bill & Melinda Gates Foundation.
Copyright © Moore et al. Open Access article distributed under the terms of CC BY.
Introduction
The associations between ﬁ rst-trimester malaria, treatment, 
and miscarriage remain poorly documented because these 
events often occur before women present to antenatal 
care.1,2 A single ﬁ rst-trimester malaria episode is associated 
with miscarriage,3 and women with ﬁ rst-trimester malaria 
who are not adequately treated are at high risk of placental 
malaria.4 Because women are usually not protected by 
preventive interventions until the second trimester,3 early 
diagnosis and eﬀ ective treatment of ﬁ rst-trimester malaria 
are essential to limit the deleterious eﬀ ects of malaria.5
Artemisinin derivatives (hereafter referred to as 
artemisinins) are the most eﬀ ective antimalarials available. 
Artemi sinin-based combination therapies are recom-
mended by the WHO for ﬁ rst-line treatment of falciparum 
malaria, except during the ﬁ rst trimester of pregnancy.6 
Animal studies have raised concerns about the safety of 
artemisinins in the ﬁ rst trimester, but data for human 
beings are scarce. In animals, artemisinins are embryotoxic 
and teratogenic because they deplete embryonic 
erythroblasts, causing miscarriage and congenital malfor-
mations (mainly cardiovascular and skeletal).7 If 
artemisinins are also embryotoxic or teratogenic in human 
beings, the embryo-sensitive period is predicted to be 
between 6 weeks’ and 13 weeks’ gestation when 
erythroblasts are the primary form of circulating red blood 
cells.8 Because of these safety concerns, quinine is still 
recommended for uncomplicated ﬁ rst-trimester falciparum 
malaria rather than artemisinins, despite being an inferior 
treatment.6 Available data for ﬁ rst-trimester artemisinin 
safety comes from observational studies of inadvertent 
treatments, which are common but rarely documented.2 
No speciﬁ c adverse eﬀ ects have been noted in human 
beings in 935 documented ﬁ rst-trimester artemisinin 
treatments (appendix p 1),9–18 which although reassuring, 
has not been suﬃ  cient to change treatment 
recommendations.6
The Shoklo Malaria Research Unit (SMRU) screens 
pregnant women frequently for malaria because there are 
no eﬀ ective preventive interventions (appendix p 3).19 
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Since 1986, prospective data have been collected on 
conﬁ rmed malaria infections, antimalarial treatment, 
and pregnancy outcomes of women attending SMRU 
antenatal clinics, providing an important source of 
observational evidence on ﬁ rst-trimester artemisinin 
safety. In this setting, a single ﬁ rst-trimester malaria 
episode (falciparum or vivax) increased the odds of 
miscarriage, but ﬁ rst-trimester artemisinin treatment 
was not associated with miscarriage.3 However, for 
analytic clarity in this earlier study women with recurrent 
infections were excluded, which reduced the number of 
artemisinin treatments to 44 and overestimated the eﬀ ect 
of malaria, because a recurrent infection in pregnancy 
depends on the fetus surviving the initial infection. Here, 
we extend this seminal study by including women with 
recurrent malaria, which might be either novel, 
recrudescent, or a relapse in the case of vivax malaria, and 
added 3 further years of data. Assessment of the safety of 
artemisinins requires weighing the risks of malaria and 
its treatment. Therefore, we sought to assess the eﬀ ect of 
both ﬁ rst-trimester malaria and artemisinin treatment on 
miscarriage and major congenital malformations.
Methods
Study design and participants
In this observational study, we assessed data from 
antenatal clinics on the Thai–Myanmar border between 
Jan 1, 1994, and Dec 31, 2013. We included women who 
presented to antenatal clinics during their ﬁ rst trimester 
with a viable fetus. Women were screened for malaria, 
and data for malaria, antimalarial treatment, and birth 
outcomes were collected. The Oxford Tropical Research 
Ethics Committee granted ethical approval for audits of 
SMRU clinical records (OXTREC 28-09), and the Tak 
Province Community Ethics Advisory Board provided 
local permission (T-CAB-4/1/2015). Data for ﬁ rst-trimester 
malaria from some of the records included in this analysis 
have been published previously.3,19–22
Procedures
At SMRU antenatal clinics, women are encouraged to 
present early and return weekly throughout their 
pregnancy for malaria screening, consisting of a ﬁ nger-
prick blood sample that is examined by trained 
microscopists using Giemsa stained thick and thin blood 
ﬁ lms (appendix p 3).5 Women are also encouraged to 
present if they feel unwell, and to deliver at SMRU 
clinics. The ﬁ rst consultation involves taking obstetric 
and medical histories, a detailed clinical examination, 
and gestational age estimation.23 With each positive 
screen, information about species, parasitaemia, 
symptoms, and treatment are recorded. Women are also 
asked about recent antimalarial treatments at out-
patient clinics, and these treatments (usually 
Research in context
Evidence before this study
We searched Scopus and PubMed for articles published up to Oct 5, 
2015, in any language, that addressed the association between 
ﬁ rst-trimester artemisinin treatment and miscarriage using the 
search terms: “malaria or plasmodium”, “pregnan*”, “*artemisinin* 
OR ACT* OR artesunate OR artemether OR Coartem”, 
“ﬁ rst-trimester OR ‘ﬁ rst trimester’ OR ‘early pregnancy’”, and 
“miscarriage* OR abortion”. One study reported on the association 
between a single ﬁ rst-trimester malaria episode and miscarriage. 
No randomised controlled trials of ﬁ rst-trimester artemisinin 
treatment were identiﬁ ed. No studies have reported on the 
association between recurrent ﬁ rst-trimester malaria and 
miscarriage. Ten observational studies of ﬁ rst-trimester artemisinin 
treatment were identiﬁ ed totalling 935 documented treatments, 
and a systematic review published in 2007. These studies showed 
no evidence of an increased risk of miscarriage or major congenital 
malformations associated with ﬁ rst-trimester artemisinin 
treatment. Importantly, only one published study examining the 
association between ﬁ rst-line artemisinin treatment and 
miscarriage accounted for left truncation, which is necessary when 
women present at varying gestations due to the declining risk of 
miscarriage as a pregnancy progresses, and few were able to 
account for confounding by indication and disease severity.
Added value of this study
Assessment of the safety of artemisinin derivatives requires 
weighing the risks of falciparum malaria against those of its 
treatment. We noted that ﬁ rst-trimester falciparum malaria 
increases the risk of miscarriage, especially after recurrence. 
However, there was no evidence that ﬁ rst-line treatment with 
an artemisinin derivative in the ﬁ rst trimester was associated 
with an increased risk of miscarriage or congenital 
malformations compared with ﬁ rst-line quinine, which is 
currently recommended by the WHO. We compared ﬁ rst-line 
treatment with an artemisinin derivative with ﬁ rst-line 
quinine in women with ﬁ rst-trimester falciparum malaria in 
an area of low seasonal transmission, and accounted for 
confounding by indication and disease severity, thereby 
separating the eﬀ ects of infection from the eﬀ ects of 
treatment. To the best of our knowledge, this study is the ﬁ rst 
to estimate the association between recurrent ﬁ rst-trimester 
malaria and miscarriage, and contributes a further 
183 documented ﬁ rst-trimester artemisinin treatments. Left 
truncation, which adjusts for the temporally changing risks of 
miscarriage and varying gestation at presentation, was also 
accounted for and is essential to avoid signiﬁ cant bias.
Implications of all the available evidence
Eﬀ ective treatment of ﬁ rst-trimester falciparum malaria is 
imperative. Our results add to a growing body of observational 
evidence that artemisinins, the most eﬀ ective antimalarials 
available, are safe in the ﬁ rst trimester of pregnancy. 
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meﬂ oquine–artesunate [MAS] for P falciparum) are 
recorded retrospectively. Presumptive malaria treatment 
is not used, and pregnancy termination is unavailable.
First-trimester non-malaria febrile morbidity was 
deﬁ ned as fever (temperature ≥37·5oC) not associated 
with malaria. Malaria was deﬁ ned as the presence of 
asexual stages of plasmodia parasites in the peripheral 
blood, counted per 500 white blood cells or 1000 red blood 
cells. Hyperparasitaemia was deﬁ ned as 4% parasitaemia 
or greater, and severe malaria was deﬁ ned according to 
signs of vital organ dysfunction. Symptomatic malaria 
was deﬁ ned as patent parasitaemia and a history of fever 
(past 48 h) or temperature 37·5oC or greater. Vivax malaria 
was treated with oral chloroquine. Falciparum malaria 
was treated with oral quinine in the ﬁ rst trimester, or an 
artemisinin-based treatment in the second and third 
trimester (either artesunate, artemether–lumefantrine, 
dihydroartemisinin–piperaquine, or meﬂ oquine–arte-
sunate). Meﬂ oquine monotherapy was given for 
falciparum malaria until 1996. Clindamycin was added to 
quinine and artesunate 7-day treatments in 2007 to 
augment eﬃ  cacy. According to WHO recommendations, 
artemisinins were given in the ﬁ rst trimester for quinine 
failures, hyperparasitaemia, severe malaria, or if the fetus 
was no longer viable.6 Details on treatment regimens and 
drug manufacturers are given in the appendix (p 4).
Outcomes
Primary exposures were malaria and ﬁ rst-line artemisinin 
treatment in the ﬁ rst trimester, deﬁ ned as less than 
14 weeks’ gestation. The primary outcome was miscarriage, 
deﬁ ned as fetal death before 28 weeks’ gestation because 
infant respiratory support is unavailable. The ability to 
determine gestation and fetal viability at SMRU improved 
after ultrasound was introduced in 2002 (appendix p 3).23,24 
The date of miscarriage was recorded consistently as the 
date of expulsion of the uterine contents, either 
spontaneously or through surgical intervention, which 
can occur some time after intrauterine death. The 
secondary outcome was major congenital malformations. 
A surface examination was done on all newborns by 
trained staﬀ ; a physician veriﬁ ed all malformations, except 
for some early neonatal deaths. Artemisinin-based 
treatments were ﬁ rst deployed in the general population 
in 1994. Therefore, we included women who presented to 
antenatal clinics during their ﬁ rst trimester with a viable 
fetus between Jan 1, 1994, and Dec 31, 2013.
Statistical analysis
We used Cox proportional hazards models accounting for 
left truncation (appendix p 5) and time-varying exposures 
for all miscarriage analyses, with censoring at the gestation 
time of miscarriage, gestation time when last seen, or 
28 weeks’ gestation. To assess the association between 
malaria and miscarriage, women entered the analysis at 
the gestation time of their ﬁ rst antenatal visit. Multivariable 
models adjusted for year of ﬁ rst consultation, gravidity, 
smoking, and ﬁ rst-trimester non-malaria febrile 
morbidity. To assess the association between ﬁ rst-line 
artemisinin treatment and miscarriage (primary analysis), 
we included women with ﬁ rst-trimester falciparum 
malaria, and compared ﬁ rst-line quinine treatment 
(including quinine plus clindamycin) with ﬁ rst-line 
meﬂ oquine monotherapy, artemisinin treatment (all 
derivatives) following quinine failure (ie, artemisinin 
rescue), and ﬁ rst-line artemisinin treatment (all 
derivatives). Women entered the analysis at the gestation 
time of their ﬁ rst falciparum malaria episode. Treatments 
given after determination of fetal non-viability were 
excluded. Multivariable models adjusted for year of ﬁ rst 
consultation, disease severity pertaining to the ﬁ rst 
falciparum malaria episode (asymptomatic, symptomatic, 
or hyperparasitaemic or severe), and ﬁ rst-trimester non-
malaria febrile morbidity. The prevalence of major 
congenital malformation was described by ﬁ rst-trimester 
falciparum malaria and ﬁ rst-line treatment. Malformations 
were grouped by organ system to increase the likelihood 
of detecting teratogenic signals.25 Data were analysed with 
Stata version 13 (StataCorp, College Station, TX, USA).
Figure 1: Study proﬁ le
P vivax=Plasmodium vivax. P malariae=Plasmodium malariae. P ovale=Plasmodium ovale. P falciparum=Plasmodium 
falciparum.
55 636 pregnancies were registered between
 1994 and 2013
25 485 pregnancies included in analysis of ﬁrst
 trimester malaria and miscarriage
 20 861 delivered
 2257 miscarried
 2367 lost to follow-up before 28 weeks
22 927 had no infections in ﬁrst trimester
 2558 had ≥1 infections in ﬁrst trimester
 1207 had ≥1 P falciparum infections
 1532 had ≥1 P vivax infections
 181 had both P falciparum and P vivax infections
30 151 excluded
 3038 not viable at ﬁrst antenatal consultation
 1462 had no estimate of gestational age
 25 651 enrolled after ﬁrst trimester
4857 excluded for analysis of major
 congenital malformations only
 2391 lost to follow-up
 2257 miscarried
 209 twins
20 628 pregnancies included in analysis
 of major congenital malformations
 175 had a major malformation
24 306 excluded
 22 927 had no infections in ﬁrst trimester
 1351 had only P vivax, P malariae, or P ovale in
 ﬁrst trimester
 8 had unknown ﬁrst-line treatment
 20 had signs of pregnancy loss before
 ﬁrst-line treatment
1179 pregnancies with ≥1 P falciparum infection in 
           ﬁrst trimester included in analysis
 971 ﬁrst-line quinine or quinine plus clindamycin
 treatments
  25 ﬁrst-line meﬂoquine monotherapy
 treatments
 183 ﬁrst-line artemisinin treatments
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Role of the funding source
The funding sources (The Wellcome Trust and The Bill & 
Melinda Gates Foundation) had no role in the study design, 
data collection, data analysis, data interpretation, writing of 
the report, or the decision to submit for publication. The 
corresponding author had full access to all data and had the 
ﬁ nal responsibility in the decision to submit for publication.
Results
Between Jan 1, 1994 and Dec 31, 2013, 55 636 pregnant 
women presented to SMRU clinics, of whom 25 485 (46%) 
presented during their ﬁ rst trimester with a viable fetus 
(ﬁ gure 1). Of these, 2257 (10%) of 23 118 miscarried, 2367 
(9%) of 25 485 were lost to follow-up before 28 weeks 
gestation, and 2558 (10%) of 25 485 had ﬁ rst-trimester 
malaria (ﬁ gure 1). Women with ﬁ rst-trimester malaria 
were more likely to miscarry or be lost to follow-up and 
tended to present for antenatal care earlier, be younger, 
be primigravid, and smoke compared with women 
without ﬁ rst-trimester malaria (all p<0·0001; table 1).
Of the 2558 women with ﬁ rst-trimester malaria, 
1207 (47%) had falciparum malaria, 1532 (60%) had vivax 
malaria, and 181 (7%) had both vivax and falciparum 
(either separate or mixed infections). Recurrent ﬁ rst-
trimester falciparum malaria occurred in 162 (13%) of 
1207 women, and recurrent ﬁ rst-trimester vivax malaria in 
139 (9%) of 1532. Most (971 [80%] of 1207) women with 
ﬁ rst-trimester falciparum malaria were treated initially 
with quinine and 183 (15%) of 1207 were treated initially 
with artemisinin (ie, ﬁ rst-line artemisinin treatment; 
table 1). Of the 971 women who received ﬁ rst-line quinine 
treatment, 129 (13%) were rescued with artemisinin 
(usually artesunate monotherapy or artesunate plus 
clindamycin) following recurrence. Of the 183 ﬁ rst-line 
artemisinin treatments, 37 (20%) were for hyper-
parasitaemia (administered orally) or severe disease 
(administered parenterally). First-line treatment of ﬁ rst-
trimester falciparum malaria occurred at a median of 
8·2 gestation weeks (IQR 5·3–11·1). Loss to follow-up was 
similar between antimalarial treatment groups, except 
women receiving meﬂ oquine–artesunate were less likely 
to be lost (p=0·0417; appendix p 6). Rates of falciparum 
malaria during pregnancy and miscarriage and the 
frequency of ﬁ rst-line quinine and artemisinin treatments 
in ﬁ rst trimester over time are shown in ﬁ gure 2.
Of 1207 women with ﬁ rst-trimester falciparum malaria, 
165 (17% of 983 followed until 28 weeks’) miscarried and 
224 (19%) were lost to follow-up compared with 1963 (9%) 
of 20 978 and 1949 (9%) of 22 927 in women with no ﬁ rst-
trimester malaria, respectively. In multivariable analyses, 
the hazard of miscarriage increased 1·61-fold (95% CI 
1·32–1·97; p<0·0001) with an initial ﬁ rst-trimester 
falciparum malaria episode, and 3·24-fold (2·24–4·68; 
p<0·0001) with recurrent ﬁ rst-trimester falciparum malaria 
(ﬁ gure 3). This association was stronger in women with 
symptomatic falciparum malaria than in women with 
asymptomatic falciparum malaria (ﬁ gure 2). A single 
ﬁ rst-trimester hyperparasitaemic or severe falciparum 
malaria episode increased the hazard of miscarriage 
4·21-fold (95% CI 2·43–7·29; p<0·0001; ﬁ gure 3). An initial 
ﬁ rst-trimester vivax malaria episode, either asymptomatic 
or symptomatic, increased the hazard of miscarriage 
slightly (ﬁ gure 3). Recurrent symptomatic ﬁ rst-trimester 
vivax malaria increased the hazard of miscarriage 2·44-fold 
(95% CI 1·01–5·88; p=0·0473; ﬁ gure 3).
Of the 1207 women with ﬁ rst-trimester falciparum 
malaria, 1179 (98%) had a known ﬁ rst-line antimalarial 
treatment and a viable fetus at the time of treatment 
(ﬁ gure 1). Most (842 [71%] of 1179) received ﬁ rst-line 
No ﬁ rst-trimester malaria 
(n=22 927)
First-trimester malaria 
(n=2558)
Miscarried* 1963 (9%) 294 (14%)
Lost to follow-up before 28 weeks’ gestation† 1949 (9%) 418 (16%)
Gestation at ﬁ rst consultation (weeks) 9·0 (7·2–11·3) [0·0–14·0] 8·4 (6·6–10·6) [0·1–14·0]
Maternal age (years) 26 (21–31) [13–51] 23 (19–30) [13–46]
13–20 5443 (24%) 909 (36%)
21–25 5959 (26%) 628 (25%)
26–30 5709 (25%) 482 (19%)
≥31 5816 (25%) 539 (21%)
Primigravid 5628 (25%) 821 (32%)
Current smoker 5362 (26%) 764 (35%)
History of miscarriage 6200 (27%) 758 (30%)
Haematocrit (ﬁ rst consultation; %) 36 (33–38) [9–52] 34 (31–37) [13–48]
Severe anaemia (haematocrit <20%) 9 (0%) 13 (1%)
Non-malaria febrile morbidity in ﬁ rst 
trimester
310 (1%) 38 (1%)
Number of antenatal malaria screens 23 (14–28) [1–40] 22 (15–28) [1–38]
Estimated gestational age from 
ultrasonography scans
16 714 (73%) 1648 (64%)
Details of initial ﬁ rst-trimester malaria
Symptoms
Asymptomatic NA 919 (36%)
Symptomatic NA 1639 (64%)
First-line treatment of ﬁ rst-trimester falciparum malaria
Quinine NA 971 (81%)
Meﬂ oquine monotherapy NA 25 (2%)
Artemisinin derivative NA 183 (15%)
Meﬂ oquine–artesunate NA 71 (6%)
Artemether–lumefantrine NA 10 (1%)
Artesunate plus clindamycin NA 50 (4%)
Artesunate monotherapy NA 49 (4%)
Dihydroartemisinin–piperaquine NA 3 (0%)
Other or unknown NA 8 (1%)
Died before administration NA 20 (2%)
Data are median (IQR) [range] or n (%). Missing: gravidity, ten; smoking status, 2853; history of miscarriage, nine; 
haematocrit, 969; and miscarriage, 2367 (ie, lost to follow up before 28 weeks’ gestation). Continuous variables were 
compared between groups using the Student’s t test for normal distribution or the Mann-Whitney U test for skewed 
distribution. Categorical variables were compared with the χ2 test. *In women followed until 28 weeks; women who 
miscarried presented for antenatal care 1·4 weeks earlier (p<0·0001), because early attendance increases the chances 
that a miscarriage will be detected. †Women lost to follow-up were slightly younger (p<0·0001), and were more likely to 
be primigravid (p<0·0001) and have ﬁ rst-trimester malaria (p<0·0001; appendix p 6). NA=not applicable. 
Table 1: Cohort demographics
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Figure 2: Frequency of ﬁ rst-line quinine and artemisinin treatments in ﬁ rst trimester and rates of falciparum malaria during pregnancy and miscarriage over time
The increase in the rate of falciparum malaria in 1998 was due to the establishment of Shoklo Malaria Research Unit antenatal clinics in migrant communities. 
Quinine or quinine plus clindamycin treatments
Artemisinin treatments
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Year of ﬁrst antenatal consultation
1 Falciparum malaria (all)
2 Asymptomatic falciparum
3 Symptomatic falciparum
4 Hyperparasitaemic/severe falciparum
5 Asymptomatic vivax
6 Symptomatic vivax
Gravidity
Current smoker
Non-malaria febrile morbidity
No malaria
Initial
Recurrent
Initial
Initial
Recurrent
Initial
Initial
Initial
Recurrent
Primigravid
Multigravid
No
No
HR (95% CI); p value
Reference group
1·61 (1·32–1·97); <0·0001
3·24 (2·24–4·68); <0·0001
1·27 (0·76–2·11); 0·3616
1·83 (1·47–2·28); <0·0001
4·92 (3·28–7·38); <0·0001
4·21 (2·43–7·29); <0·0001
1·21 (0·89–1·65); 0·2286
1·27 (0·96–1·68); 0·0943
2·44 (1·01–5·88); 0·0473
Reference group
1·48 (1·30–1·68); <0·0001
Reference group
1·38 (1·25–1·53); <0·0001
Reference group
2·59 (1·99–3·37); <0·0001
18 995 (91%)
702 (84%)
113 (77%)
165 (92%)
482 (82%)
54 (67%)
31 (67%)
479 (89%)
454 (88%)
33 (87%)
15 592 (89%)
5245 (93%)
13 651 (92%)
4860 (88%)
20 596 (90%)
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132 (16%)
33 (23%)
15 (8%)
109 (18%)
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15 (33%)
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398 (7%)
1172 (8%)
685 (12%)
2192 (10%)
65 (21%)
0·5 1·0 2·0 8·0
Yes
Yes
Delivered, N (%) Miscarried, N (%)
Increased risk of miscarriageDecreased risk of miscarriage
Figure 3: Association between initial and recurrent ﬁ rst-trimester malaria and miscarriage
Models include women lost to follow-up before 28 weeks (until gestation time last seen), but percentage calculations for delivered or miscarried do not. Models for 
falciparum malaria (1–4) include women that might have also had ﬁ rst-trimester vivax, malariae, or ovale malaria. See appendix p 8 for associations in women with only 
ﬁ rst-trimester falciparum malaria. Models for vivax malaria (5–6) exclude women who also had ﬁ rst-trimester falciparum malaria. Models 2 and 5 exclude women with 
symptomatic malaria. Models 3 and 6 exclude women with asymptomatic infections. Model 4 excludes women with uncomplicated infections. Models were adjusted for 
year (by stratiﬁ cation due to non-proportional hazards [p<0·001]), gravidity, current smoking status, and non-malaria febrile morbidity in ﬁ rst trimester. Age and 
previous miscarriage were omitted from multivariable models due to collinearity with gravidity. Adjusted results for gravidity, current smoking status, and febrile 
morbidity in ﬁ rst trimester are shown from Model 1. 146 women had recurrent ﬁ rst-trimester falciparum malaria (136 had two and ten had three episodes). 13 women 
had recurrent (two) asymptomatic ﬁ rst-trimester falciparum malaria. 81 women had recurrent symptomatic ﬁ rst-trimester falciparum malaria (75 had two, and six had 
three episodes). 17 women had recurrent (two episodes) asymptomatic ﬁ rst-trimester vivax malaria, and none miscarried. 38 women had recurrent (two) symptomatic 
ﬁ rst-trimester vivax malaria. See appendix p 8 for a table version of this ﬁ gure, including univariable associations.
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quinine (including quinine plus clindamycin), 129 (11%) 
of 1179 received ﬁ rst-line quinine followed by artemisinin 
(artemisinin rescue), 25 (2%) of 1179 received ﬁ rst-line 
meﬂ oquine monotherapy, and 183 (16%) of 1179 received 
ﬁ rst-line artemisinin. First-line artemisinin treatment 
was not associated with miscarriage when compared with 
women who received ﬁ rst-line quinine only (HR 0·78 
[95% CI 0·45–1·34]; p=0·3645; ﬁ gure 4). Five (3%) of 
183 women received two ﬁ rst-trimester artemisinin 
treatments; one miscarried, and four delivered.
Because animal studies suggest a theoretical embryo-
sensitive window in human beings of 6–13 weeks’ 
gestation, we also estimated the association between 
ﬁ rst-line artemisinin treatment and miscarriage before, 
during, and after this window.9 First-line artemisinin 
treatments before the embryo-sensitive window were 
associated with a non-signiﬁ cant decrease in the hazard 
of miscarriage (HR 0·54 [95% CI 0·25– 1·15]; p=0·1108), 
whereas treatments during the embryo-sensitive window 
were not associated with a changed hazard of miscarriage 
(1·15 [0·46–2·87]; p=0·7602; ﬁ gure 4).
Of note, a high proportion of women who received ﬁ rst-
line meﬂ oquine–artesunate miscarried (15 [21%] of 71), 
and most miscarriages in the artemisinin treatment group 
(15 [63%] of 23) were in women who received meﬂ oquine–
artesunate speciﬁ cally. Further, a third of women who 
received meﬂ oquine–artesunate during the embryo-
sensitive window miscarried (eight [33%] of 24). However, 
this might be explained by the circumstances of this 
treatment: women received meﬂ oquine–artesunate from 
outpatient clinics (rather than antenatal clinics) where they 
presented because of illness before they became aware of 
their pregnancy. Additionally, meﬂ oquine–artesunate 
treat ments at outpatient clinics were given at earlier 
gestations than for the other treatments when women are 
at greater risk of miscarriage (meﬂ oquine–artesunate: 
3·8 weeks [IQR 1·9–7·4]; quinine: 10·1 [7·5–11·8]; other 
artemisinins: 12·4 [9·0– 13·3]; appendix p 7).
20 628 women presented for antenatal care between 1994 
and 2013 and gave birth to a singleton newborn, of whom 
175 (1%) of 20 628 (95% CI 0·73–0·98) had newborns with 
a major congenital malformation (ﬁ gure 1). The prevalence 
of congenital malformations in the newborn babies of 
women with no ﬁ rst-trimester malaria was 0·84% 
(158/18 803 [95% CI 0·71–0·98]; table 2). The prevalence of 
congenital malformations was similar in the newborns of 
women with ﬁ rst-trimester vivax malaria (0·59% [95% CI 
0·22–1·27]). In the newborn babies of women with 
uncomplicated ﬁ rst-trimester falciparum malaria, 
malformation prevalence was slightly higher (1·29% 
[10/773]; [95% CI 0·62–2·37]), but did not diﬀ er between 
the newborn of women who received ﬁ rst-line quinine 
(1·25% [8/641; [95% CI 0·54–2·44]) and those of women 
who received ﬁ rst-line artemisinin (2/109 [microphthalmia; 
imperforate anus]; 1·83% [95% CI 0·22–6·47]; p=0·7551; 
table 2). Two other newborns of mothers who had 
hyperparasitaemic or severe ﬁ rst-trimester falciparum 
malaria had a malformation (syndactyly; cleft lip and palate; 
9·09% [2/22]; [95% CI 1·12–29·16]); both were of mothers 
who received ﬁ rst-line artemisinin, but only eight women 
No malaria 
(n=18 803)
Uncomplicated falciparum 
malaria (n=773)*
Hyperparasitaemic or severe 
falciparum malaria (n=31)*
Quinine 
(n=641)
Artemisinin 
(n=109)
Quinine 
(n=8)
Artemisinin 
(n=22)
Multiple 26 (17%) 1 (13%) 0 0 0
Syndromic 4 (3%) 0 0 0 0
CNS 33 (21%) 1 (13%)† 0 0 0
Ears, eyes, face, or neck 24 (15%) 0 1 (50%)‡ 0 0
Circulatory 13 (8%) 1 (13%)§ 0 0 0
Respiratory 2 (1%) 0 0 0 0
Digestive 59 (37%) 2¶ (25%) 1|| (50%) 0 1** (50%)
Genital 19 (12%) 0 0 0 0
Renal 6 (4%) 0 0 0 0
Musculoskeletal 42 (27%) 4†† (50%) 0 0 1‡‡ (50%)
Skin 4 (3%) 0 0 0 0
Other 1 (1%) 0 0 0 0
Data are n (%). *24 women received ﬁ rst-line meﬂ oquine or had unknown ﬁ rst-line treatment (zero malformations). 
†Anencephaly (treated at 10 weeks’ gestation). ‡Microphthalmia (8 weeks’). §Heart defect (7 weeks’). ¶Cleft lip and palate 
(10 weeks’); cleft lip and palate (9 weeks’). ||Imperforated anus (6 weeks’). **Cleft lip and palate (14 weeks’). ††Polydactyly 
(12 weeks’); polydactyly (12 weeks’); syndactyly and talipes (11 weeks’); syndactyly (9 weeks’). ‡‡Syndactyly (13 weeks’). 
Table 2: Major congenital malformations by ﬁ rst-line treatment of ﬁ rst-trimester falciparum malaria 
by organ system
Figure 4: Association between ﬁ rst-line treatment of ﬁ rst-trimester falciparum malaria and 
miscarriage (n=1179)
Models were adjusted for severity of the ﬁ rst falciparum malaria episode (asymptomatic, symptomatic, or 
hyperparasitaemic or severe), non-malaria febrile morbidity in the ﬁ rst trimester, and year of ﬁ rst consultation. See 
appendix p 9 for a table version of this ﬁ gure, including univariable associations. *Hazard ratios are shown for 
treatments occurring before (<6 weeks’ gestation) and during (≥6 and <13 weeks’ gestation) the embryosensitive 
window. †Artemisinin rescue after quinine failure refers to artemisinin-based treatment in ﬁ rst trimester following 
failure of ﬁ rst-line treatment with quinine or quinine plus clindamycin. No miscarriages occurred in women who 
received artemisinin treatment after the embryo-sensitive window (≥13 and <14 weeks’ gestation). We did a subgroup 
analysis excluding women with asymptomatic malaria (n=919); the association between artemisinin treatment and 
miscarriage changed by <5% (appendix p 9). We did a subgroup analysis in women attending before 2007 whose 
gestational age was estimated from ultrasound biometry, because the accuracy of gestational age estimates aﬀ ects the 
accuracy of the gestation time of antimalarial treatment, and quinine plus clindamycin succeeded quinine 
monotherapy in 2007 (n=469); associations were in the same direction but of greater magnitude (appendix p 9). 
Quinine or quinine plus clindamycin
Artemisinin rescue 
after quinine failure†
Mefloquine
monotherapy
Artemisinin-based treatments (all)
First trimester
Before*
During*
First trimester
Before*
During*
Reference group 
Reference group 
Reference group 
1·18 (0·67–2·10); 0·5613
0·54 (0·13–2·31); 0·4082
0·78 (0·45–1·34); 0·3645
0·54 (0·25–1·15); 0·1108
1·15 (0·46–2·87); 0·7602
750 (89%)
93 (76%)
585 (91%)
111 (86%)
23 (92%)
160 (87%)
50 (82%)
64 (84%)
92 (11%)
30 (24%)
57 (9%)
18 (14%)
2 (8%)
23 (13%)
11 (18%)
12 (16%)
HR (95% CI); p valueDelivered, 
N (%)
Miscarried, 
N (%)
Increased risk of miscarriageDecreased risk of miscarriage
0·2 0·5 1·0 2·0 4·0
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received ﬁ rst-line quinine (table 2). No newborns of 
mothers who received artemisinin in ﬁ rst trimester had the 
skeletal or cardiovascular malformations as reported in 
animal studies.
Discussion
First-trimester falciparum malaria increases the risk of 
miscarriage, especially after recurrence, but this large 
prospective observational study found no evidence that 
ﬁ rst-line treatment with an artemisinin derivative was 
associated with an increased risk of miscarriage or 
congenital malformations. Assessment of the safety of 
artemisinin treatment during pregnancy requires 
weighing the risks of falciparum malaria against those of 
its treatment. This is the ﬁ rst study to estimate the eﬀ ects 
of initial and recurrent ﬁ rst-trimester malaria, its 
symptomatology, and its treatment on miscarriage.
Legitimate ethical concerns regarding randomised-
controlled trials of ﬁ rst-trimester artemisinin treatment 
have meant that only observational studies have been 
done to date, and these have not adjusted for confounding 
by indication and disease severity in assessing risks and 
beneﬁ ts.26 A major strength of this study is that it was 
possible to adjust for these important confounders by 
comparing with nearly 1000 women who received 
quinine treatment (appendix p 5). Left truncation, which 
adjusts for the temporally changing risks of miscarriage 
and varying gestation at presentation, was also accounted 
for since this is essential to avoid bias.27 Nevertheless, 
this study still has limitations common to observational 
designs. Data were collected over a long period of time, 
relatively few ﬁ rst-trimester artemisinin treatments 
were given, toxicities other than miscarriage and major 
mal formations detectable at birth from surface 
examination were not captured, and all artemisinin 
derivatives were analysed together. Several associations 
of considerable magnitude had wide CIs that crossed 
null, and we cannot rule out potential confounding 
eﬀ ects of time and unmeasured variables, or residual 
confounding by disease severity. Furthermore, women 
with ﬁ rst-trimester malaria were more likely to be lost to 
follow-up, raising the possibility of informative right 
censoring, but this would underestimate the eﬀ ect of 
malaria (appendix p 5).
We noted no evidence that ﬁ rst-line treatment with an 
artemisinin derivative increased the rate of miscarriage 
compared with ﬁ rst-line treatment with quinine. There 
was a higher risk of miscarriage in women who received 
an artemisinin derivative during the putative embryo-
sensitive window, but this might be explained at least in 
part by the administration of meﬂ oquine–artesunate at 
earlier gestations to symptomatic women in the routine 
outpatient clinics compared with the active surveillance 
of antenatal clinics. In rats, embryotoxicity of artesunate 
was attenuated when co-administered with meﬂ oquine.28 
Primates, including human beings, might be less 
sensitive to the eﬀ ects of artemisinins because of 
diﬀ erences in placentation and the visceral yolk sac, 
which could result in diﬀ erent levels of embryonic 
exposure to artemisinins.7,29 Additionally, a 3-day 
artemisinin regimen means that the exposure period is 
relatively short in human beings because organogenesis 
is 3 days in rats but 3 months in human beings.7,29 
Therefore, artemisinin-induced depletion of embryonic 
erythro blasts severe enough to cause miscarriage in rats 
might not translate to human beings, but could still 
cause congenital malformations.
We cannot draw ﬁ rm conclusions on the possible eﬀ ects 
of ﬁ rst-trimester artemisinin treatment on congenital 
malformations because of relatively small numbers of 
treatments and cases. Furthermore, the prevalence of 
major congenital malformations is most likely an 
underestimation because only those detectable at birth 
from surface examination and heart auscultation were 
recorded routinely, and major malformations (particularly 
cardiovascular) are often not detected or conﬁ rmed until 
later in life. Only four newborns whose mother received 
ﬁ rst-line artemisinin treatment during ﬁ rst trimester had 
a major congenital malformation, and the organ systems 
involved were inconsistent with the types of malformations 
induced by artemisinins in animal studies.
These results have important implications for malaria 
treatment and control policies, and future studies of 
artemisinin safety. Recurrent ﬁ rst-trimester vivax malaria 
is associated with miscarriage, yet radical cure is not 
possible during pregnancy with currently available drugs. 
First-trimester falciparum malaria is strongly associated 
with miscarriage, especially after recurrence. We noted 
no evidence of harm associated with ﬁ rst-line artemisinin 
treatment of ﬁ rst-trimester falciparum malaria. Quinine 
is comparatively poorly tolerated and associated with a 
shorter time to recurrence than artemisinin in pregnant 
women.30 Furthermore, women who received artemi-
sinins following quinine failure were more likely to 
miscarry than those who received ﬁ rst-line artemisinin 
treatment. Early and eﬀ ective antimalarial treatment is 
imperative, especially because current preventive 
measures do not adequately cover early pregnancy.3 
Artemisinins are the most eﬀ ective antimalarials 
available and have been recommended as ﬁ rst-line 
treatment in the general population by the WHO since 
2006. Yet, artemisinin safety in ﬁ rst trimester is still a 
concern. This study contributes a further 183 well-
documented ﬁ rst-trimester artemisinin treatments, and 
adds to a growing body of observational evidence 
supporting the use of artemisinins in the ﬁ rst trimester 
of pregnancy.3,11,12,14–18,22,31 In view of the wide availability of 
artemisinin-based combination therapies, their excellent 
tolerability and eﬃ  cacy, the likely reduced future 
availability of quinine, and the rarity of congenital 
malformations, now might be the time to endorse the 
use of artemisinin derivatives for the treatment of ﬁ rst-
trimester falciparum malaria, accompanied by robust 
pharmacovigilance.
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